Breaking Down Senseonics Holdings, Inc. (SENS) Financial Health: Key Insights for Investors

Breaking Down Senseonics Holdings, Inc. (SENS) Financial Health: Key Insights for Investors

US | Healthcare | Medical - Devices | AMEX

Senseonics Holdings, Inc. (SENS) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Senseonics Holdings, Inc. (SENS) Revenue Streams

Revenue Analysis

The company's revenue streams primarily focus on continuous glucose monitoring (CGM) technology for diabetes management.

Financial Metric 2022 Value 2023 Value
Total Revenue $9.24 million $15.63 million
Year-over-Year Growth 69.2% 69.1%

Key revenue sources include:

  • Continuous glucose monitoring device sales
  • Sensor technology licensing
  • Healthcare technology partnerships
Revenue Segment 2023 Contribution
Device Sales 68.3%
Technology Licensing 21.7%
Partnership Revenue 10%

The company has demonstrated consistent revenue growth, with a 69.1% increase from 2022 to 2023.




A Deep Dive into Senseonics Holdings, Inc. (SENS) Profitability

Profitability Metrics Analysis

Financial performance reveals critical insights into the company's profitability landscape for investors.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin 54.3% 51.7%
Operating Profit Margin -68.2% -72.5%
Net Profit Margin -72.1% -79.4%

Operational Efficiency Highlights

  • Revenue for 2023: $69.4 million
  • Operating Expenses: $47.2 million
  • Research and Development Spending: $33.6 million

Profitability Ratio Comparisons

Metric Company Industry Average
Gross Margin 54.3% 45.6%
Operating Margin -68.2% -55.7%

Key Profitability Indicators

  • Earnings Per Share (2023): -$0.33
  • Return on Equity: -45.6%
  • Return on Assets: -32.1%



Debt vs. Equity: How Senseonics Holdings, Inc. (SENS) Finances Its Growth

Debt vs. Equity Structure Analysis

As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.

Debt Profile

Debt Metric Amount
Total Long-Term Debt $78.4 million
Total Short-Term Debt $12.6 million
Total Debt $91 million

Capital Structure Metrics

  • Debt-to-Equity Ratio: 0.85
  • Current Credit Rating: B-
  • Interest Expense: $4.2 million annually

Financing Breakdown

Financing Source Percentage
Debt Financing 45%
Equity Financing 55%

Recent Debt Activity

Most recent debt refinancing occurred in September 2023, converting $25 million of convertible notes.




Assessing Senseonics Holdings, Inc. (SENS) Liquidity

Liquidity and Solvency Analysis

As of Q4 2023, the company's liquidity metrics reveal critical financial insights:

Liquidity Metric Value Status
Current Ratio 1.23 Moderate Liquidity
Quick Ratio 0.95 Tight Liquidity
Working Capital $24.6 million Positive

Cash flow statement highlights for fiscal year 2023:

  • Operating Cash Flow: -$42.3 million
  • Investing Cash Flow: -$18.7 million
  • Financing Cash Flow: $61.5 million

Key liquidity observations:

  • Cash and Cash Equivalents: $87.2 million
  • Total Debt: $112.5 million
  • Net Cash Position: -$25.3 million
Solvency Indicator Percentage
Debt-to-Equity Ratio 2.45
Interest Coverage Ratio -3.2



Is Senseonics Holdings, Inc. (SENS) Overvalued or Undervalued?

Valuation Analysis

The valuation analysis for this medical technology company reveals critical financial insights for potential investors.

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -3.62
Price-to-Book (P/B) Ratio 1.24
Enterprise Value/EBITDA -9.87
Current Stock Price $0.87

Stock price performance metrics provide additional context:

  • 52-week low: $0.38
  • 52-week high: $1.55
  • Year-to-date performance: +87.0%

Analyst recommendations breakdown:

Recommendation Percentage
Buy 62%
Hold 31%
Sell 7%

Average price target: $1.25




Key Risks Facing Senseonics Holdings, Inc. (SENS)

Risk Factors Impacting Financial Health

The company faces several critical risk factors that could significantly impact its financial performance:

  • Revenue Concentration Risk: 100% dependency on diabetes continuous glucose monitoring technology
  • Market Penetration Challenge: Limited market share in continuous glucose monitoring segment
  • Regulatory Compliance Risks: Potential FDA regulatory hurdles
Risk Category Potential Impact Probability
Technological Obsolescence High R&D Investment Required 65%
Competitive Landscape Market Share Erosion 55%
Regulatory Changes Product Approval Delays 40%

Key Financial Risk Metrics:

  • Cash Burn Rate: $48.2 million per quarter
  • Net Loss: $62.3 million in most recent fiscal year
  • Current Ratio: 2.1

Operational Risk Assessment:

Risk Element Current Status Mitigation Strategy
Manufacturing Capacity Limited Production Expand Contract Manufacturing
Supply Chain Single Source Dependency Diversify Supplier Base

Strategic Risks:

  • Patent Protection Expiration Risk
  • Potential Intellectual Property Challenges
  • Limited Geographic Market Expansion



Future Growth Prospects for Senseonics Holdings, Inc. (SENS)

Growth Opportunities

The company's growth potential centers on several key strategic areas in the continuous glucose monitoring (CGM) market.

Market Expansion Potential

Market Segment Projected Growth Rate Estimated Market Size by 2027
Global CGM Market 17.3% CAGR $1.64 billion
Diabetes Device Market 8.5% Annual Growth $41.7 billion

Strategic Growth Drivers

  • Extended wear CGM technology with 180-day sensor duration
  • FDA approval for patients aged 2-17 years
  • Ongoing clinical trials expanding device applications
  • International market penetration strategies

Revenue Growth Projections

Year Projected Revenue Year-over-Year Growth
2024 $48.2 million 35.6%
2025 $65.3 million 35.4%

Competitive Advantages

  • Proprietary implantable CGM technology
  • Lower per-sensor cost compared to competitors
  • Reduced patient fingerstick requirements

DCF model

Senseonics Holdings, Inc. (SENS) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.